Fig. 1From: Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort studyStudy population. Eligible patients were classified into four groups: low-risk initial treatment-responsive group (n = 116), low-risk initial treatment-resistant group (n = 28), high-risk initial treatment-responsive group (n = 27), and high-risk initial treatment-resistant group (n = 10)Back to article page